ACHIEVE-1: Orforglipron Phase 3 trial (NCT05971940)
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 559
- actual
- Start
- 9 Aug 2023 (actual)
- Primary completion
- 3 Apr 2025 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo | Placebo comparator | Drug: Placebo | Participants received once daily (QD) doses of orforglipron-matching placebo capsules administered orally, over a period of 40 weeks. |
| 3 mg Orforglipron | Experimental | Drug: Orforglipron | Participants received orforglipron capsules administered orally QD, starting at 1 milligram (mg) and increasing by 1 mg every 4 weeks until reaching a targeted dose of 3 mg, which was then maintained up to week 40. |
| 12 mg Orforglipron | Experimental | Drug: Orforglipron | Participants received orforglipron capsules administered orally QD, starting at 1 mg and increasing every 4 weeks until reaching a targeted dose of 12 mg, which was then maintained up to week 40. |
| 36 mg Orforglipron | Experimental | Drug: Orforglipron | Participants received orforglipron capsules administered orally QD, starting at 1 mg and increasing every 4 weeks until reaching a targeted dose of 36 mg, which was then maintained up to week 40. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Change From Baseline in HbA1c | Baseline, Week 40 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percentage of Participants With an HbA1c Target Value of < 7.0% (53 mmol/Mol) | Week 40 |
| Percentage of Participants With an HbA1c Target Value of ≤6.5% (48 mmol/Mol) | Week 40 |
| Change From Baseline in Fasting Serum Glucose (FSG) | Baseline, Week 40 |
| Percent Change From Baseline in Body Weight | Baseline, Week 40 |
| Change From Baseline in Body Weight | Baseline, Week 40 |
| Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol | Baseline, Week 40 |
| Percent Change From Baseline in Triglycerides | Baseline, Week 40 |
| Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) | Baseline, Week 40 |
| Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction | Week 40 |
| Change From Baseline in Systolic Blood Pressure (SBP) | Baseline, Week 40 |
| Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores | Baseline, Week 40 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05971940.
ACHIEVE-1 in early type 2 diabetes treated with diet and exercise
Participants were randomised 1:1:1:1 to orforglipron 3, 12 or 36 mg or placebo once daily for 40 weeks, and had an HbA1c of 7.0% to 9.5%.[2]
HbA1c fell by 1.24, 1.47 and 1.48 points on 3, 12 and 36 mg against 0.41 on placebo.[2]
Body weight changed by -4.5%, -5.8% and -7.6% across the orforglipron arms and -1.7% on placebo.[2]
Permanent discontinuation due to adverse events occurred in 4.4 to 7.8% of orforglipron recipients and 1.4% of placebo recipients.[2]
Sources
- 1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
Found an error? Report a correction.